Independent study shows Pillcheck improves treatment for depression and anxiety
A randomized controlled trial showed that people suffering from depression and anxiety recovered faster when their medications were optimized using Pillcheck pharmacogenetics testing (also known as pharmacogenomics or PGx testing). The study evaluated the impact of pharmacogenomics-guided prescribing versus standard antidepressant treatment of depression and anxiety in three large community pharmacies. Pillcheck technology supported community pharmacists in providing evidence-based PGx-guided recommendations for patient therapy. Depression, generalized anxiety and disability improved faster for participants who received PGx-guided treatment than those who received standard treatment.
Results were published on February 28, 2021. Click the image below to read the full journal article.